Serveur d'exploration sur le lymphœdème

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Neuropathic and cerebrovascular correlates of hearing loss in Fabry disease

Identifieur interne : 007701 ( Main/Merge ); précédent : 007700; suivant : 007702

Neuropathic and cerebrovascular correlates of hearing loss in Fabry disease

Auteurs : M. Ries [États-Unis] ; H. J. Kim [États-Unis] ; C. K. Zalewski [États-Unis] ; M. A. Mastroianni [États-Unis] ; D. F. Moore [Canada, États-Unis] ; R. O. Brady [États-Unis] ; J. M. Dambrosia [États-Unis] ; R. Schiffmann [États-Unis] ; C. C. Brewer [États-Unis]

Source :

RBID : ISTEX:35ED38C09071598D8C8BA1F373EA9CD22EB75163

Abstract

Fabry disease, OMIM 301500, is a progressive multisystem storage disorder due to the deficiency of α-galactosidase A (GALA). Neurological and vascular manifestations of this disorder with regard to hearing loss have not been analysed quantitatively in large cohorts. We conducted a retrospective cross sectional analysis of hearing loss in 109 male and female patients with Fabry disease who were referred to and seen at the Clinical Center of the National Institutes of Health, Bethesda, MD, USA on natural history and enzyme replacement study protocols. There were 85 males aged 6–58 years (mean 31 years, SD 13) and 24 females aged 22–72 years (mean 42 years, SD 12). All patients underwent a comprehensive audiological evaluation. In addition, cerebral white matter lesions, peripheral neuropathy, and kidney function were quantitatively assessed. HL95, defined as a hearing threshold above the 95th percentile for age and gender matched normal controls, was present in 56% [95% CI (42.2–67.2)] of the males. Prevalence of HL95 was lower in the group of patients with residual GALA enzyme activity compared with those without detectable activity (33% versus 63%) HL95 was present in the low-, mid- and high-frequency ranges for all ages. Male patients with HL95 had a higher microvascular cerebral white matter lesion load [1.4, interquartile range (IQR) 0–30.1 ± versus 0, IQR 0–0], more pronounced cold perception deficit [19.4 ± 5.5 versus 13.5 ± 5.5 of just noticeable difference (JND) units] and lower kidney function [creatinine: 1.6 ± 1.2 versus 0.77 ± 0.2 mg/dl; blood urea nitrogen (BUN): 20.1 ± 14.1 versus 10.3 ± 3.28 mg/dl] than those without HL95 (P < 0.001). Of the females, 38% had HL95. There was no significant association with cold perception deficit, creatinine or BUN in the females. Word recognition and acoustic reflexes analyses suggested a predominant cochlear involvement. We conclude that hearing loss involving all frequency regions significantly contributes to morbidity in patients with Fabry disease. Our quantitative analysis suggests a correlation of neuropathic and vascular damage with hearing loss in the males. Residual GALA activity appears to have a protective effect against hearing loss.

Url:
DOI: 10.1093/brain/awl310

Links toward previous steps (curation, corpus...)


Links to Exploration step

ISTEX:35ED38C09071598D8C8BA1F373EA9CD22EB75163

Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Neuropathic and cerebrovascular correlates of hearing loss in Fabry disease</title>
<author>
<name sortKey="Ries, M" sort="Ries, M" uniqKey="Ries M" first="M." last="Ries">M. Ries</name>
</author>
<author>
<name sortKey="Kim, H J" sort="Kim, H J" uniqKey="Kim H" first="H. J." last="Kim">H. J. Kim</name>
</author>
<author>
<name sortKey="Zalewski, C K" sort="Zalewski, C K" uniqKey="Zalewski C" first="C. K." last="Zalewski">C. K. Zalewski</name>
</author>
<author>
<name sortKey="Mastroianni, M A" sort="Mastroianni, M A" uniqKey="Mastroianni M" first="M. A." last="Mastroianni">M. A. Mastroianni</name>
</author>
<author>
<name sortKey="Moore, D F" sort="Moore, D F" uniqKey="Moore D" first="D. F." last="Moore">D. F. Moore</name>
</author>
<author>
<name sortKey="Brady, R O" sort="Brady, R O" uniqKey="Brady R" first="R. O." last="Brady">R. O. Brady</name>
</author>
<author>
<name sortKey="Dambrosia, J M" sort="Dambrosia, J M" uniqKey="Dambrosia J" first="J. M." last="Dambrosia">J. M. Dambrosia</name>
</author>
<author>
<name sortKey="Schiffmann, R" sort="Schiffmann, R" uniqKey="Schiffmann R" first="R." last="Schiffmann">R. Schiffmann</name>
</author>
<author>
<name sortKey="Brewer, C C" sort="Brewer, C C" uniqKey="Brewer C" first="C. C." last="Brewer">C. C. Brewer</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:35ED38C09071598D8C8BA1F373EA9CD22EB75163</idno>
<date when="2007" year="2007">2007</date>
<idno type="doi">10.1093/brain/awl310</idno>
<idno type="url">https://api.istex.fr/document/35ED38C09071598D8C8BA1F373EA9CD22EB75163/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001890</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001890</idno>
<idno type="wicri:Area/Istex/Curation">001890</idno>
<idno type="wicri:Area/Istex/Checkpoint">001394</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001394</idno>
<idno type="wicri:doubleKey">0006-8950:2007:Ries M:neuropathic:and:cerebrovascular</idno>
<idno type="wicri:source">PMC</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1950668</idno>
<idno type="RBID">PMC:1950668</idno>
<idno type="wicri:Area/Pmc/Corpus">003351</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">003351</idno>
<idno type="wicri:Area/Pmc/Curation">003350</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">003350</idno>
<idno type="wicri:Area/Pmc/Checkpoint">003C50</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">003C50</idno>
<idno type="wicri:Area/Ncbi/Merge">002481</idno>
<idno type="wicri:Area/Ncbi/Curation">002481</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002481</idno>
<idno type="wicri:doubleKey">0006-8950:2006:Ries M:neuropathic:and:cerebrovascular</idno>
<idno type="wicri:Area/Main/Merge">007701</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main" xml:lang="en">Neuropathic and cerebrovascular correlates of hearing loss in Fabry disease</title>
<author>
<name sortKey="Ries, M" sort="Ries, M" uniqKey="Ries M" first="M." last="Ries">M. Ries</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and StrokeBethesda, MD</wicri:regionArea>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Correspondence to: Raphael Schiffmann MD, Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 9000 Rockville Pike, Room 3D03, Bethesda, MD 20892-1260</wicri:regionArea>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Kim, H J" sort="Kim, H J" uniqKey="Kim H" first="H. J." last="Kim">H. J. Kim</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Otolaryngology Branch, National Institute on Deafness and Other Communication DisordersBethesda, MD</wicri:regionArea>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Correspondence to: Raphael Schiffmann MD, Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 9000 Rockville Pike, Room 3D03, Bethesda, MD 20892-1260</wicri:regionArea>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Zalewski, C K" sort="Zalewski, C K" uniqKey="Zalewski C" first="C. K." last="Zalewski">C. K. Zalewski</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Otolaryngology Branch, National Institute on Deafness and Other Communication DisordersBethesda, MD</wicri:regionArea>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Correspondence to: Raphael Schiffmann MD, Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 9000 Rockville Pike, Room 3D03, Bethesda, MD 20892-1260</wicri:regionArea>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Mastroianni, M A" sort="Mastroianni, M A" uniqKey="Mastroianni M" first="M. A." last="Mastroianni">M. A. Mastroianni</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and StrokeBethesda, MD</wicri:regionArea>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Correspondence to: Raphael Schiffmann MD, Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 9000 Rockville Pike, Room 3D03, Bethesda, MD 20892-1260</wicri:regionArea>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Moore, D F" sort="Moore, D F" uniqKey="Moore D" first="D. F." last="Moore">D. F. Moore</name>
<affiliation wicri:level="4">
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Section of Neurology, Department of internal MedicineUniversity of Manitoba</wicri:regionArea>
<placeName>
<settlement type="city">Winnipeg</settlement>
<region type="state">Manitoba</region>
</placeName>
<orgName type="university">Université du Manitoba</orgName>
</affiliation>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Correspondence to: Raphael Schiffmann MD, Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 9000 Rockville Pike, Room 3D03, Bethesda, MD 20892-1260</wicri:regionArea>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Brady, R O" sort="Brady, R O" uniqKey="Brady R" first="R. O." last="Brady">R. O. Brady</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and StrokeBethesda, MD</wicri:regionArea>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Correspondence to: Raphael Schiffmann MD, Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 9000 Rockville Pike, Room 3D03, Bethesda, MD 20892-1260</wicri:regionArea>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Dambrosia, J M" sort="Dambrosia, J M" uniqKey="Dambrosia J" first="J. M." last="Dambrosia">J. M. Dambrosia</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Biostatistics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of HealthBethesda, MD</wicri:regionArea>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Correspondence to: Raphael Schiffmann MD, Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 9000 Rockville Pike, Room 3D03, Bethesda, MD 20892-1260</wicri:regionArea>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Schiffmann, R" sort="Schiffmann, R" uniqKey="Schiffmann R" first="R." last="Schiffmann">R. Schiffmann</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and StrokeBethesda, MD</wicri:regionArea>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Correspondence to: Raphael Schiffmann MD, Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 9000 Rockville Pike, Room 3D03, Bethesda, MD 20892-1260</wicri:regionArea>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Brewer, C C" sort="Brewer, C C" uniqKey="Brewer C" first="C. C." last="Brewer">C. C. Brewer</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Otolaryngology Branch, National Institute on Deafness and Other Communication DisordersBethesda, MD</wicri:regionArea>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Correspondence to: Raphael Schiffmann MD, Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 9000 Rockville Pike, Room 3D03, Bethesda, MD 20892-1260</wicri:regionArea>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">Brain</title>
<idno type="ISSN">0006-8950</idno>
<idno type="eISSN">1460-2156</idno>
<imprint>
<publisher>Oxford University Press</publisher>
<date type="published" when="2007-01">2007-01</date>
<biblScope unit="volume">130</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="143">143</biblScope>
<biblScope unit="page" to="150">150</biblScope>
</imprint>
<idno type="ISSN">0006-8950</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0006-8950</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass></textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Fabry disease, OMIM 301500, is a progressive multisystem storage disorder due to the deficiency of α-galactosidase A (GALA). Neurological and vascular manifestations of this disorder with regard to hearing loss have not been analysed quantitatively in large cohorts. We conducted a retrospective cross sectional analysis of hearing loss in 109 male and female patients with Fabry disease who were referred to and seen at the Clinical Center of the National Institutes of Health, Bethesda, MD, USA on natural history and enzyme replacement study protocols. There were 85 males aged 6–58 years (mean 31 years, SD 13) and 24 females aged 22–72 years (mean 42 years, SD 12). All patients underwent a comprehensive audiological evaluation. In addition, cerebral white matter lesions, peripheral neuropathy, and kidney function were quantitatively assessed. HL95, defined as a hearing threshold above the 95th percentile for age and gender matched normal controls, was present in 56% [95% CI (42.2–67.2)] of the males. Prevalence of HL95 was lower in the group of patients with residual GALA enzyme activity compared with those without detectable activity (33% versus 63%) HL95 was present in the low-, mid- and high-frequency ranges for all ages. Male patients with HL95 had a higher microvascular cerebral white matter lesion load [1.4, interquartile range (IQR) 0–30.1 ± versus 0, IQR 0–0], more pronounced cold perception deficit [19.4 ± 5.5 versus 13.5 ± 5.5 of just noticeable difference (JND) units] and lower kidney function [creatinine: 1.6 ± 1.2 versus 0.77 ± 0.2 mg/dl; blood urea nitrogen (BUN): 20.1 ± 14.1 versus 10.3 ± 3.28 mg/dl] than those without HL95 (P < 0.001). Of the females, 38% had HL95. There was no significant association with cold perception deficit, creatinine or BUN in the females. Word recognition and acoustic reflexes analyses suggested a predominant cochlear involvement. We conclude that hearing loss involving all frequency regions significantly contributes to morbidity in patients with Fabry disease. Our quantitative analysis suggests a correlation of neuropathic and vascular damage with hearing loss in the males. Residual GALA activity appears to have a protective effect against hearing loss.</div>
</front>
</TEI>
<double doi="10.1093/brain/awl310">
<ISTEX>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Neuropathic and cerebrovascular correlates of hearing loss in Fabry disease</title>
<author>
<name sortKey="Ries, M" sort="Ries, M" uniqKey="Ries M" first="M." last="Ries">M. Ries</name>
</author>
<author>
<name sortKey="Kim, H J" sort="Kim, H J" uniqKey="Kim H" first="H. J." last="Kim">H. J. Kim</name>
</author>
<author>
<name sortKey="Zalewski, C K" sort="Zalewski, C K" uniqKey="Zalewski C" first="C. K." last="Zalewski">C. K. Zalewski</name>
</author>
<author>
<name sortKey="Mastroianni, M A" sort="Mastroianni, M A" uniqKey="Mastroianni M" first="M. A." last="Mastroianni">M. A. Mastroianni</name>
</author>
<author>
<name sortKey="Moore, D F" sort="Moore, D F" uniqKey="Moore D" first="D. F." last="Moore">D. F. Moore</name>
</author>
<author>
<name sortKey="Brady, R O" sort="Brady, R O" uniqKey="Brady R" first="R. O." last="Brady">R. O. Brady</name>
</author>
<author>
<name sortKey="Dambrosia, J M" sort="Dambrosia, J M" uniqKey="Dambrosia J" first="J. M." last="Dambrosia">J. M. Dambrosia</name>
</author>
<author>
<name sortKey="Schiffmann, R" sort="Schiffmann, R" uniqKey="Schiffmann R" first="R." last="Schiffmann">R. Schiffmann</name>
</author>
<author>
<name sortKey="Brewer, C C" sort="Brewer, C C" uniqKey="Brewer C" first="C. C." last="Brewer">C. C. Brewer</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:35ED38C09071598D8C8BA1F373EA9CD22EB75163</idno>
<date when="2007" year="2007">2007</date>
<idno type="doi">10.1093/brain/awl310</idno>
<idno type="url">https://api.istex.fr/document/35ED38C09071598D8C8BA1F373EA9CD22EB75163/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001890</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001890</idno>
<idno type="wicri:Area/Istex/Curation">001890</idno>
<idno type="wicri:Area/Istex/Checkpoint">001394</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001394</idno>
<idno type="wicri:doubleKey">0006-8950:2007:Ries M:neuropathic:and:cerebrovascular</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main" xml:lang="en">Neuropathic and cerebrovascular correlates of hearing loss in Fabry disease</title>
<author>
<name sortKey="Ries, M" sort="Ries, M" uniqKey="Ries M" first="M." last="Ries">M. Ries</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and StrokeBethesda, MD</wicri:regionArea>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Correspondence to: Raphael Schiffmann MD, Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 9000 Rockville Pike, Room 3D03, Bethesda, MD 20892-1260</wicri:regionArea>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Kim, H J" sort="Kim, H J" uniqKey="Kim H" first="H. J." last="Kim">H. J. Kim</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Otolaryngology Branch, National Institute on Deafness and Other Communication DisordersBethesda, MD</wicri:regionArea>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Correspondence to: Raphael Schiffmann MD, Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 9000 Rockville Pike, Room 3D03, Bethesda, MD 20892-1260</wicri:regionArea>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Zalewski, C K" sort="Zalewski, C K" uniqKey="Zalewski C" first="C. K." last="Zalewski">C. K. Zalewski</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Otolaryngology Branch, National Institute on Deafness and Other Communication DisordersBethesda, MD</wicri:regionArea>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Correspondence to: Raphael Schiffmann MD, Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 9000 Rockville Pike, Room 3D03, Bethesda, MD 20892-1260</wicri:regionArea>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Mastroianni, M A" sort="Mastroianni, M A" uniqKey="Mastroianni M" first="M. A." last="Mastroianni">M. A. Mastroianni</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and StrokeBethesda, MD</wicri:regionArea>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Correspondence to: Raphael Schiffmann MD, Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 9000 Rockville Pike, Room 3D03, Bethesda, MD 20892-1260</wicri:regionArea>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Moore, D F" sort="Moore, D F" uniqKey="Moore D" first="D. F." last="Moore">D. F. Moore</name>
<affiliation wicri:level="4">
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Section of Neurology, Department of internal MedicineUniversity of Manitoba</wicri:regionArea>
<placeName>
<settlement type="city">Winnipeg</settlement>
<region type="state">Manitoba</region>
</placeName>
<orgName type="university">Université du Manitoba</orgName>
</affiliation>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Correspondence to: Raphael Schiffmann MD, Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 9000 Rockville Pike, Room 3D03, Bethesda, MD 20892-1260</wicri:regionArea>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Brady, R O" sort="Brady, R O" uniqKey="Brady R" first="R. O." last="Brady">R. O. Brady</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and StrokeBethesda, MD</wicri:regionArea>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Correspondence to: Raphael Schiffmann MD, Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 9000 Rockville Pike, Room 3D03, Bethesda, MD 20892-1260</wicri:regionArea>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Dambrosia, J M" sort="Dambrosia, J M" uniqKey="Dambrosia J" first="J. M." last="Dambrosia">J. M. Dambrosia</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Biostatistics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of HealthBethesda, MD</wicri:regionArea>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Correspondence to: Raphael Schiffmann MD, Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 9000 Rockville Pike, Room 3D03, Bethesda, MD 20892-1260</wicri:regionArea>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Schiffmann, R" sort="Schiffmann, R" uniqKey="Schiffmann R" first="R." last="Schiffmann">R. Schiffmann</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and StrokeBethesda, MD</wicri:regionArea>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Correspondence to: Raphael Schiffmann MD, Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 9000 Rockville Pike, Room 3D03, Bethesda, MD 20892-1260</wicri:regionArea>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Brewer, C C" sort="Brewer, C C" uniqKey="Brewer C" first="C. C." last="Brewer">C. C. Brewer</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Otolaryngology Branch, National Institute on Deafness and Other Communication DisordersBethesda, MD</wicri:regionArea>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Correspondence to: Raphael Schiffmann MD, Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 9000 Rockville Pike, Room 3D03, Bethesda, MD 20892-1260</wicri:regionArea>
<placeName>
<region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">Brain</title>
<idno type="ISSN">0006-8950</idno>
<idno type="eISSN">1460-2156</idno>
<imprint>
<publisher>Oxford University Press</publisher>
<date type="published" when="2007-01">2007-01</date>
<biblScope unit="volume">130</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="143">143</biblScope>
<biblScope unit="page" to="150">150</biblScope>
</imprint>
<idno type="ISSN">0006-8950</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0006-8950</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass></textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Fabry disease, OMIM 301500, is a progressive multisystem storage disorder due to the deficiency of α-galactosidase A (GALA). Neurological and vascular manifestations of this disorder with regard to hearing loss have not been analysed quantitatively in large cohorts. We conducted a retrospective cross sectional analysis of hearing loss in 109 male and female patients with Fabry disease who were referred to and seen at the Clinical Center of the National Institutes of Health, Bethesda, MD, USA on natural history and enzyme replacement study protocols. There were 85 males aged 6–58 years (mean 31 years, SD 13) and 24 females aged 22–72 years (mean 42 years, SD 12). All patients underwent a comprehensive audiological evaluation. In addition, cerebral white matter lesions, peripheral neuropathy, and kidney function were quantitatively assessed. HL95, defined as a hearing threshold above the 95th percentile for age and gender matched normal controls, was present in 56% [95% CI (42.2–67.2)] of the males. Prevalence of HL95 was lower in the group of patients with residual GALA enzyme activity compared with those without detectable activity (33% versus 63%) HL95 was present in the low-, mid- and high-frequency ranges for all ages. Male patients with HL95 had a higher microvascular cerebral white matter lesion load [1.4, interquartile range (IQR) 0–30.1 ± versus 0, IQR 0–0], more pronounced cold perception deficit [19.4 ± 5.5 versus 13.5 ± 5.5 of just noticeable difference (JND) units] and lower kidney function [creatinine: 1.6 ± 1.2 versus 0.77 ± 0.2 mg/dl; blood urea nitrogen (BUN): 20.1 ± 14.1 versus 10.3 ± 3.28 mg/dl] than those without HL95 (P < 0.001). Of the females, 38% had HL95. There was no significant association with cold perception deficit, creatinine or BUN in the females. Word recognition and acoustic reflexes analyses suggested a predominant cochlear involvement. We conclude that hearing loss involving all frequency regions significantly contributes to morbidity in patients with Fabry disease. Our quantitative analysis suggests a correlation of neuropathic and vascular damage with hearing loss in the males. Residual GALA activity appears to have a protective effect against hearing loss.</div>
</front>
</TEI>
</ISTEX>
<PMC>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Neuropathic and cerebrovascular correlates of hearing loss in Fabry disease</title>
<author>
<name sortKey="Ries, M" sort="Ries, M" uniqKey="Ries M" first="M." last="Ries">M. Ries</name>
<affiliation wicri:level="1">
<nlm:aff id="A1"> Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea> Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, Bethesda, MD</wicri:regionArea>
<wicri:noRegion>MD</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Kim, H J" sort="Kim, H J" uniqKey="Kim H" first="H. J." last="Kim">H. J. Kim</name>
<affiliation wicri:level="1">
<nlm:aff id="A2"> Otolaryngology Branch, National Institute on Deafness and Other Communication Disorders, Bethesda, MD, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea> Otolaryngology Branch, National Institute on Deafness and Other Communication Disorders, Bethesda, MD</wicri:regionArea>
<wicri:noRegion>MD</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Zalewski, C K" sort="Zalewski, C K" uniqKey="Zalewski C" first="C. K." last="Zalewski">C. K. Zalewski</name>
<affiliation wicri:level="1">
<nlm:aff id="A2"> Otolaryngology Branch, National Institute on Deafness and Other Communication Disorders, Bethesda, MD, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea> Otolaryngology Branch, National Institute on Deafness and Other Communication Disorders, Bethesda, MD</wicri:regionArea>
<wicri:noRegion>MD</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Mastroianni, M A" sort="Mastroianni, M A" uniqKey="Mastroianni M" first="M. A." last="Mastroianni">M. A. Mastroianni</name>
<affiliation wicri:level="1">
<nlm:aff id="A1"> Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea> Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, Bethesda, MD</wicri:regionArea>
<wicri:noRegion>MD</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Moore, D F" sort="Moore, D F" uniqKey="Moore D" first="D. F." last="Moore">D. F. Moore</name>
<affiliation wicri:level="4">
<nlm:aff id="A4"> Section of Neurology, Department of internal Medicine, University of Manitoba, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea> Section of Neurology, Department of internal Medicine, University of Manitoba</wicri:regionArea>
<placeName>
<settlement type="city">Winnipeg</settlement>
<region type="state">Manitoba</region>
</placeName>
<orgName type="university">Université du Manitoba</orgName>
</affiliation>
</author>
<author>
<name sortKey="Brady, R O" sort="Brady, R O" uniqKey="Brady R" first="R. O." last="Brady">R. O. Brady</name>
<affiliation wicri:level="1">
<nlm:aff id="A1"> Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea> Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, Bethesda, MD</wicri:regionArea>
<wicri:noRegion>MD</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Dambrosia, J M" sort="Dambrosia, J M" uniqKey="Dambrosia J" first="J. M." last="Dambrosia">J. M. Dambrosia</name>
<affiliation wicri:level="1">
<nlm:aff id="A3"> Biostatistics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea> Biostatistics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD</wicri:regionArea>
<wicri:noRegion>MD</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Schiffmann, R" sort="Schiffmann, R" uniqKey="Schiffmann R" first="R." last="Schiffmann">R. Schiffmann</name>
<affiliation wicri:level="1">
<nlm:aff id="A1"> Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea> Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, Bethesda, MD</wicri:regionArea>
<wicri:noRegion>MD</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Brewer, C C" sort="Brewer, C C" uniqKey="Brewer C" first="C. C." last="Brewer">C. C. Brewer</name>
<affiliation wicri:level="1">
<nlm:aff id="A2"> Otolaryngology Branch, National Institute on Deafness and Other Communication Disorders, Bethesda, MD, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea> Otolaryngology Branch, National Institute on Deafness and Other Communication Disorders, Bethesda, MD</wicri:regionArea>
<wicri:noRegion>MD</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PMC</idno>
<idno type="pmid">17105746</idno>
<idno type="pmc">1950668</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1950668</idno>
<idno type="RBID">PMC:1950668</idno>
<idno type="doi">10.1093/brain/awl310</idno>
<date when="2006">2006</date>
<idno type="wicri:Area/Pmc/Corpus">003351</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">003351</idno>
<idno type="wicri:Area/Pmc/Curation">003350</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">003350</idno>
<idno type="wicri:Area/Pmc/Checkpoint">003C50</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">003C50</idno>
<idno type="wicri:Area/Ncbi/Merge">002481</idno>
<idno type="wicri:Area/Ncbi/Curation">002481</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002481</idno>
<idno type="wicri:doubleKey">0006-8950:2006:Ries M:neuropathic:and:cerebrovascular</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a" type="main">Neuropathic and cerebrovascular correlates of hearing loss in Fabry disease</title>
<author>
<name sortKey="Ries, M" sort="Ries, M" uniqKey="Ries M" first="M." last="Ries">M. Ries</name>
<affiliation wicri:level="1">
<nlm:aff id="A1"> Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea> Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, Bethesda, MD</wicri:regionArea>
<wicri:noRegion>MD</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Kim, H J" sort="Kim, H J" uniqKey="Kim H" first="H. J." last="Kim">H. J. Kim</name>
<affiliation wicri:level="1">
<nlm:aff id="A2"> Otolaryngology Branch, National Institute on Deafness and Other Communication Disorders, Bethesda, MD, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea> Otolaryngology Branch, National Institute on Deafness and Other Communication Disorders, Bethesda, MD</wicri:regionArea>
<wicri:noRegion>MD</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Zalewski, C K" sort="Zalewski, C K" uniqKey="Zalewski C" first="C. K." last="Zalewski">C. K. Zalewski</name>
<affiliation wicri:level="1">
<nlm:aff id="A2"> Otolaryngology Branch, National Institute on Deafness and Other Communication Disorders, Bethesda, MD, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea> Otolaryngology Branch, National Institute on Deafness and Other Communication Disorders, Bethesda, MD</wicri:regionArea>
<wicri:noRegion>MD</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Mastroianni, M A" sort="Mastroianni, M A" uniqKey="Mastroianni M" first="M. A." last="Mastroianni">M. A. Mastroianni</name>
<affiliation wicri:level="1">
<nlm:aff id="A1"> Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea> Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, Bethesda, MD</wicri:regionArea>
<wicri:noRegion>MD</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Moore, D F" sort="Moore, D F" uniqKey="Moore D" first="D. F." last="Moore">D. F. Moore</name>
<affiliation wicri:level="4">
<nlm:aff id="A4"> Section of Neurology, Department of internal Medicine, University of Manitoba, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea> Section of Neurology, Department of internal Medicine, University of Manitoba</wicri:regionArea>
<placeName>
<settlement type="city">Winnipeg</settlement>
<region type="state">Manitoba</region>
</placeName>
<orgName type="university">Université du Manitoba</orgName>
</affiliation>
</author>
<author>
<name sortKey="Brady, R O" sort="Brady, R O" uniqKey="Brady R" first="R. O." last="Brady">R. O. Brady</name>
<affiliation wicri:level="1">
<nlm:aff id="A1"> Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea> Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, Bethesda, MD</wicri:regionArea>
<wicri:noRegion>MD</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Dambrosia, J M" sort="Dambrosia, J M" uniqKey="Dambrosia J" first="J. M." last="Dambrosia">J. M. Dambrosia</name>
<affiliation wicri:level="1">
<nlm:aff id="A3"> Biostatistics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea> Biostatistics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD</wicri:regionArea>
<wicri:noRegion>MD</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Schiffmann, R" sort="Schiffmann, R" uniqKey="Schiffmann R" first="R." last="Schiffmann">R. Schiffmann</name>
<affiliation wicri:level="1">
<nlm:aff id="A1"> Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea> Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, Bethesda, MD</wicri:regionArea>
<wicri:noRegion>MD</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Brewer, C C" sort="Brewer, C C" uniqKey="Brewer C" first="C. C." last="Brewer">C. C. Brewer</name>
<affiliation wicri:level="1">
<nlm:aff id="A2"> Otolaryngology Branch, National Institute on Deafness and Other Communication Disorders, Bethesda, MD, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea> Otolaryngology Branch, National Institute on Deafness and Other Communication Disorders, Bethesda, MD</wicri:regionArea>
<wicri:noRegion>MD</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series>
<title level="j">Brain : a journal of neurology</title>
<idno type="ISSN">0006-8950</idno>
<idno type="eISSN">1460-2156</idno>
<imprint>
<date when="2006">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass></textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">
<p id="P1">Fabry disease, OMIM 301500, is a progressive multisystem storage disorder due to the deficiency of
<italic>α</italic>
-galactosidase A (GALA). Neurological and vascular manifestations of this disorder with regard to hearing loss have not been analysed quantitatively in large cohorts. We conducted a retrospective cross sectional analysis of hearing loss in 109 male and female patients with Fabry disease who were referred to and seen at the Clinical Center of the National Institutes of Health, Bethesda, MD, USA on natural history and enzyme replacement study protocols. There were 85 males aged 6–58 years (mean 31 years, SD 13) and 24 females aged 22–72 years (mean 42 years, SD 12). All patients underwent a comprehensive audiological evaluation. In addition, cerebral white matter lesions, peripheral neuropathy, and kidney function were quantitatively assessed. HL
<sub>95</sub>
, defined as a hearing threshold above the 95th percentile for age and gender matched normal controls, was present in 56% [95% CI (42.2–67.2)] of the males. Prevalence of HL
<sub>95</sub>
was lower in the group of patients with residual GALA enzyme activity compared with those without detectable activity (33% versus 63%) HL
<sub>95</sub>
was present in the low-, mid- and high-frequency ranges for all ages. Male patients with HL
<sub>95</sub>
had a higher microvascular cerebral white matter lesion load [1.4, interquartile range (IQR) 0–30.1 ± versus 0, IQR 0–0], more pronounced cold perception deficit [19.4 ± 5.5 versus 13.5 ± 5.5 of just noticeable difference (JND) units] and lower kidney function [creatinine: 1.6 ± 1.2 versus 0.77 ± 0.2 mg/dl; blood urea nitrogen (BUN): 20.1 ± 14.1 versus 10.3 ± 3.28 mg/dl] than those without HL
<sub>95</sub>
(
<italic>P</italic>
< 0.001). Of the females, 38% had HL
<sub>95</sub>
. There was no significant association with cold perception deficit, creatinine or BUN in the females. Word recognition and acoustic reflexes analyses suggested a predominant cochlear involvement. We conclude that hearing loss involving all frequency regions significantly contributes to morbidity in patients with Fabry disease. Our quantitative analysis suggests a correlation of neuropathic and vascular damage with hearing loss in the males. Residual GALA activity appears to have a protective effect against hearing loss.</p>
</div>
</front>
</TEI>
</PMC>
</double>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 007701 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 007701 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    Main
   |étape=   Merge
   |type=    RBID
   |clé=     ISTEX:35ED38C09071598D8C8BA1F373EA9CD22EB75163
   |texte=   Neuropathic and cerebrovascular correlates of hearing loss in Fabry disease
}}

Wicri

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024